Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Moodys
Colorcon
Dow
Mallinckrodt

Last Updated: November 15, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 209299

See Plans and Pricing

« Back to Dashboard

NDA 209299 describes TAVALISSE, which is a drug marketed by Rigel Pharms Inc and is included in one NDA. It is available from one supplier. There are fourteen patents protecting this drug. Additional details are available on the TAVALISSE profile page.

The generic ingredient in TAVALISSE is fostamatinib disodium. One supplier is listed for this compound. Additional details are available on the fostamatinib disodium profile page.
Summary for 209299
Tradename:TAVALISSE
Applicant:Rigel Pharms Inc
Ingredient:fostamatinib disodium
Patents:14
Generic Entry Opportunity Date for 209299
Generic Entry Date for 209299*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 209299
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TAVALISSE fostamatinib disodium TABLET;ORAL 209299 NDA Rigel Pharmaceuticals, Inc. 71332-001 71332-001-01 60 TABLET in 1 BOTTLE (71332-001-01)
TAVALISSE fostamatinib disodium TABLET;ORAL 209299 NDA Rigel Pharmaceuticals, Inc. 71332-002 71332-002-01 60 TABLET in 1 BOTTLE (71332-002-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 100MG BASE
Approval Date:Apr 17, 2018TE:RLD:Yes
Regulatory Exclusivity Expiration:Apr 17, 2025
Regulatory Exclusivity Use:FOR THE TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
Regulatory Exclusivity Expiration:Apr 17, 2023
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:  Start TrialPatent Expiration:Sep 4, 2026Product Flag?Substance Flag?YDelist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Harvard Business School
Medtronic
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.